Verona Pharma's Ohtuvayre launch drives rapid growth and global expansion. Read about the VRNA stock's Q1 results, analyst ...

Verona Pharma's VRNA short percent of float has fallen 11.62% since its last report. The company recently reported that it ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

Verona Pharma plc (NASDAQ:VRNA) is one of the 10 biotech stocks screaming a buy. On June 17, Roth Capital increased its price ...

Verona Pharma, now valued at $7.65 billion, has been expanding its sales force, with 30 new representatives set to start in July. This will bring the total sales team to approximately 120 people ...

We recently published a list of Jim Cramer Put These 14 Stocks Under the Microscope. In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other ...

Verona Pharma Announces June 2025 Investor Conference Participation. LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the ...

On Thursday, Piper Sandler analysts reaffirmed their Overweight rating for Verona Pharma stock (NASDAQ: NASDAQ: VRNA) and maintained a $76.00 price target, as the stock trades near its 52-week high of ...

A high-level overview of Verona Pharma plc (VRNA) stock. View (VRNA) real-time stock price, chart, news, analysis, analyst reviews and more.

Verona Pharma’s stock has reached an unprecedented peak, setting an all-time high at $77.08, with a substantial market capitalization of $6.74 billion. According to InvestingPro data, analysts have ...

Verona Pharma plc (NASDAQ:VRNA) is among the 10 Best Growth Stocks Under $100 to Buy Now. Analysts at Jefferies have raised ...